Bendamustine/Idelalisib/Rituximab Regimen

Preferred Label : Bendamustine/Idelalisib/Rituximab Regimen;

NCIt synonyms : IBR; IBR Regimen; Idelalisib/Bendamustine/Rituximab; Idelalisib/Bendamustine/Rituximab Regimen; Bendamustine/Idelalisib/Rituximab; BR and Idelalisib;

NCIt related terms : Bendamustine and Rituximab (BR) and Idelalisib; Bendamustine and Rituximab-rite (BR) and Idelalisib; Bendamustine and Rituximab-rixi (BR) and Idelalisib; Bendamustine and Rituximab-abbs (BR) and Idelalisib; Bendamustine and Rituximab-blit (BR) and Idelalisib; Bendamustine and Rituximab-arrx (BR) and Idelalisib; Bendamustine and Rituximab-pvvr (BR) and Idelalisib; Bendamustine and Rituximab-rixa (BR) and Idelalisib;

NCIt definition : A regimen consisting of bendamustine, idelalisib and rituximab that can be used in the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL).;

NCI Metathesaurus CUI : CL969485;

Codes from synonyms : 12338; 127902; 128059; 128216; 127745; 128373; 128530; 128687;

Details

Origin ID

C160549;

UMLS CUI

C5202634;

Semantic type(s)
- Therapeutic or Preventive Procedure [UMLS semantic type]
chemotherapy_regimen_has_component
- Bendamustine Hydrochloride [NCIt concept]
- Idelalisib [NCIt concept]
- Rituximab [NCIt concept]
concept_is_in_subset
- HemOnc Regimen Terminology [NCIt concept]
- Multi-agent Therapeutic Regimens [NCIt concept]
- Pharmacotherapy Regimens [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients